The next cell therapy move takes Astra into neoantigens
For $200m Astrazeneca buys Neogene, and Alaunos’s long-suffering investors can just look on.
Pulling back the curtain on Astrazeneca’s Car-T work
Astra’s stealthy move into cell therapy has yielded a truly novel cancer target, and the company could be in clinical trials soon.
GSK deals cell therapy another setback
GSK ends long-running work targeting NY-ESO-1, and that’s bad news for Adaptimmune as well as Lyell.
Prame looks like the real deal
But can the novel antigen be targeted effectively? Immatics reckons it can, with the right dose and the right manufacturing process.
Esmo 2022 movers – Kras backfires
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
It’s official: Roche is a Car-T player
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.
Asco 2022 movers – cell therapy wins, but it’s not the whole story
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
Asco 2022 – great expectations for Adicet, Arcellx and PMV
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
